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Should serial fetal biometry be used in all pregnancies?
Serial measurements of an infant’s height, weight, 
and head circumference to monitor growth have 
been a cornerstone of routine paediatric care. This 
practice is based on the premise that detection of 
growth disorders, such as failure to thrive, can be 
manifestations of malnutrition, metabolic and 
genetic disorders, or infection and can be treated.1 The 
frequency with which infant growth is monitored is 
associated with growth velocity. A general principle 
in developmental biology is that organisms are most 
susceptible to insults during periods of rapid growth.2,3 
Therefore, it is somewhat paradoxical that even though 
the human growth rate is particularly rapid during fetal 
life, monitoring such growth in women with low-risk 
pregnancies is not part of standard obstetrical care. 
This situation persists despite overwhelming evidence 
that fetal growth disorders are risk factors for adverse 
perinatal outcome and can predispose these infants 
to adult chronic diseases.4 Routine assessment of fetal 
growth in women with low-risk pregnancies is not 
done because of a lack of compelling evidence that 
serial fetal biometry improves detection of smallness at 
birth and reduces infant morbidity.5 A groundbreaking 
study by Ulla Sovio and colleagues,6 published in 
The Lancet, now shows that serial assessment of fetal 
biometry in all pregnancies improves the detection 
of small-for-gestational-age (SGA) neonates and 
identiﬁ es a subset at risk for morbidity.
Sovio and colleagues6 report results of a prospective 
cohort study of unselected nulliparous women with 
a singleton viable gestation who underwent a dating 
ultrasound examination (typically at 10–14 weeks’ 
gestation). Women who agreed to participate in the 
study were scheduled to undergo serial ultrasound 
examinations at roughly 20, 28, and 36 weeks of 
gestational age. About half of the patients (1666 [42%] 
of 3977 women) also underwent clinically indicated 
third trimester scans, in accordance with the UK’s 
National Institute of Health and Care Excellence 
guidelines for low-risk7 and high-risk pregnancies 
(eg, mothers who have diabetes, hypertension, or 
low symphyseal-fundal height).8 Detection of SGA in 
the cohort was initially analysed on the basis of the 
results of selective or clinically indicated sonography. 
The analysis was then repeated with the results from 
universal or research sonography, and the diagnostic 
a very welcome alternative to surgery in patients with 
anal precancer.
The path from the proof-of-principle vaccine 
developed by Trimble and colleagues1 to the ideal 
immunotherapy, permitting us to make optimum use 
of the sensitivity of HPV screening, is obviously not 
straightforward. But it is encouraging to see that the 
ﬁ rst step has been taken.
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eﬀ ectiveness of both approaches to detect SGA at birth 
were compared.
The results of fetal biometry and the anatomical 
survey to detect congenital anomalies at the time 
of the 20 weeks examination were reported for the 
entire cohort. However, the results of the 28 weeks 
and 36 weeks research ultrasound examinations were 
concealed from both clinicians and patients. This 
masking allowed for observation of the natural 
outcome of pregnancy in a subset of fetuses who 
had growth restriction or were small at birth and in 
whom no intervention was implemented, because 
these conditions had not been detected by a clinically 
indicated ultrasound. Ethical justiﬁ cation for concealing 
results derived from research ultrasounds was that third 
trimester sonography has not been shown to improve 
pregnancy outcome,5 and is not recommended by 
professional societies. Yet women could still beneﬁ t 
from participating in this study6 because incidental 
ﬁ ndings of importance noted during research 
sonographic examinations were conveyed to both 
patients and their clinicians (ie, congenital anomalies, 
placenta praevia, oligohydramnios, or non-cephalic 
presentation at 36 weeks’ gestational age).
The key results from Sovio and colleagues’ study6 
were, ﬁ rst, that universal sonography in the third 
trimester almost tripled the detection of SGA compared 
with clinically-indicated sonography (from 69 [20%] 
of 352, to 199 [57%] of 352). Second, among SGA 
neonates, those with an estimated weight of less than 
the 10th percentile and a fetal abdominal circumference 
growth velocity at the lowest decile or less (ie, 
abnormal) were at increased risk for neonatal morbidity 
(relative risk 3·9, 95% CI 1·9–8·1), whereas those with 
an estimated fetal weight less than the 10th percentile 
and abdominal circumference growth velocity above 
the lowest decile were not. Importantly, about 70% 
of fetuses diagnosed as SGA did not have abnormal 
abdominal circumference growth velocity. Third, 
abnormal umbilical artery or uterine artery Doppler 
velocimetry were not associated with an increased risk 
of neonatal morbidity.
However, the improved sensitivity in detection of 
SGA neonates achieved by universal sonography came 
at a cost, because for every additional SGA newborn 
detected, about two false positive diagnoses were 
made.6 Therefore, whether universal sonography for 
fetal growth assessment should be implemented 
in clinical practice needs consideration of risks and 
beneﬁ ts. Immediate challenges to address are, amongst 
others, to improve the accuracy of the sonographic 
diagnosis of SGA, to identify a small fetus at risk for 
morbidity, and to determine the interventions that 
could improve neonatal outcome.
The biometric parameters that Sovio and colleagues6 
assessed were head circumference, abdominal 
circumference, femur length, and estimated fetal 
weight, with the diagnosis of SGA being based only on 
estimated fetal weight. Errors inherent in sonographic 
estimations of fetal weight are well known. The value of 
other sonographic parameters that are representative 
of fetal soft tissue characteristics in improving the 
diagnostic accuracy of SGA, and of novel statistical 
approaches that allow for personalised assessments 
of third trimester fetal growth9 (ie, individualised fetal 
growth assessment) need to be explored. Although 
Doppler velocimetry of the uterine and umbilical 
arteries did not improve diagnostic eﬀ ectiveness in 
Sovio and colleagues’ study,6 other Doppler parameters 
might be useful. An emerging body of evidence 
suggests that assessment of the middle cerebral artery 
and the cerebroplacental ratio10 could help to identify 
a fetus at risk for neonatal complications, particularly 
near term when most diagnoses of SGA are made. 
Moreover, biomarkers in maternal blood and urine 
could assist in further enhancing the identiﬁ cation 
of an SGA fetus at risk. Indeed, maternal plasma 
concentrations of angiogenic and anti-angiogenic 
factors in preterm gestations with SGA fetuses are able 
to identify mothers at increased risk for pre-eclampsia, 
or those needing an indicated preterm delivery.11 Such 
biomarkers seem to be of value to identify patients 
at risk of fetal death at or near term,12 and might be 
helpful in pregnancies with an SGA fetus in which the 
risk for fetal death is increased.
We envision that a combination of fetal biometry, 
Doppler velocimetry, and biomarkers (such as placental 
growth factor, soluble vascular endothelial growth factor 
receptor 1, soluble endoglin, pregnancy-associated 
plasma protein A, human chorionic gonadotropin, 
and α-fetoprotein) would allow for identiﬁ cation of 
a population of SGA fetuses at especially high risk. 
Interventional studies focused on additional frequent 
fetal surveillance, timing of delivery, or administration 
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of pharmacological agents could all be subjects of 
investigation.
Th e major contribution of Sovio and colleagues’ 
important study6 is that universal serial fetal biometry 
improves the detection of SGA neonates, and that 
assessment of abdominal circumference growth 
velocity contributes to identiﬁ cation of a subset of 
newborn babies at an increased risk of morbidity. This 
work, coupled with the development of international 
standards for fetal growth,13 provides a solid foundation 
for future research to establish if routine fetal growth 
assessment can improve pregnancy outcome. Whether 
this can be accomplished with an observational 
study using standard obstetrical interventions, or if 
a randomised clinical trial is needed, is an important 
issue that warrants careful consideration.
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